Nachrichten und Videos - ABLIVA AB [CBOE] - Seite 2

NeuroVive Enrolls First Subject in its KL1333 Phase Ia/b Clinical Study PR Newswire LUND, Sweden, March 19, 2019 LUND, Sweden , March 19, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the first healthy volunteer in the company's KL1333 phase Ia/b study has been screened and will be enrolled into the study. First subject first visit in NeuroVive's KL1333 phase Ia/b study was completed on 18 March 2019 . The main aim of this second...

NeuroVive Receives SEK 28.2 Million in a Directed New Share Issue PR Newswire LUND, Sweden, March 7, 2019 LUND, Sweden , March 7, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF ) t oday announced that the company has successfully conducted a directed new issue of shares, which has raised proceeds to NeuroVive of SEK 28.2 million before issue costs. These proceeds will be used primarily to accelerate clinical development activities. NeuroVive's Board of...

NeuroVive Enters Commercial Partnership With Oroboros Instruments on Mitochondrial Medicine Research Compounds PR Newswire LUND, Sweden, Feb. 21, 2019 LUND, Sweden , Feb. 21, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has entered into an exclusive agreement to license and supply two of its first generation of succinate/malonate prodrugs as research tool compounds to Oroboros Instruments, a global supplier of...

NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders PR Newswire LUND, Sweden, Nov. 15, 2018 LUND, Sweden , Nov. 15, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the company has been awarded SEK 1.5 million as a first tranche of total SEK 5 million in funding from Vinnova, Sweden's innovation agency, and the Swelife call, for intensified development in the NVP015...

NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders PR Newswire LUND, Sweden, Nov. 15, 2018 LUND, Sweden , Nov. 15, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the company has been awarded SEK 1.5 million as a first tranche of total SEK 5 million in funding from Vinnova, Sweden's innovation agency, and the Swelife call, for intensified development in the NVP015...

NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders PR Newswire LUND, Sweden, Nov. 15, 2018 LUND, Sweden , Nov. 15, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the company has been awarded SEK 1.5 million as a first tranche of total SEK 5 million in funding from Vinnova, Sweden's innovation agency, and the Swelife call, for intensified development in the NVP015...

NeuroVive Receives KL1333 Clinical Trial Regulatory Approval PR Newswire LUND, Sweden, Oct. 10, 2018 LUND, Sweden , Oct. 10, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that it has received approval of its clinical trial application concerning a planned phase I KL1333 study in patients and healthy volunteers from the UK regulatory authority, Medicines and Healthcare products Regulatory Agency (MHRA). KL1333 is a first-in-class...

Edison Investment Research Limited Edison Investment Research Limited: Edison issues outlook on NeuroVive Pharmaceutical (NVP) 05-Oct-2018 / 11:14 GMT/BST London, UK, 5 October 2018 Edison issues outlook on NeuroVive Pharmaceutical (NVP) On 18 June 2018, NeuroVive (NVP:SS) announced that it had out-licensed a subset of compounds from its NVP015 programme (succinate prodrugs) to BridgeBio, a private biotech based in California, targeting Leber's Hereditary Optic Neuropathy (LHON) under new...

NeuroVive Reports First NeuroSTAT Clinical Efficacy Signal in TBI PR Newswire LUND, Sweden, Oct. 4, 2018 LUND, Sweden , Oct. 4, 2018 NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the successful completion of biomarker analyses of samples from its clinical study in severe traumatic brain injury patients (the CHIC study) using the company's investigational compound NeuroSTAT. The results provide an early signal of efficacy derived from time-based changes in...

NeuroVive Receives Positive FDA Feedback on its NeuroSTAT TBI Development Plan PR Newswire LUND, Sweden, Sept. 6 2018 LUND, Sweden , Sept. 6 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced positive U.S. Food and Drug Administration (FDA) feedback on its NeuroSTAT clinical development plan for the treatment of moderate to severe Traumatic Brain Injury (TBI) at a pre-IND (Investigational New Drug) meeting. The main feedback requested was on...

NeuroVive's NVP015 Program Will be Accelerated Through Award of Major Research Grant to Children's Hospital of Philadelphia PR Newswire LUND, Sweden, Aug. 28, 2018 LUND, Sweden , Aug. 28, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that scientists at the company's research partner the Children's Hospital of Philadelphia (CHOP) have received a three-year grant (W81XWH-17-PRMRP-TTDA), in total of $4,090,281 USD , from the U.S. Department...

NeuroVive Pharmaceutical AB Interim Report January - June 2018 NeuroVive out-licenses targeted LHON therapy to BridgeBio PR Newswire STOCKHOLM, Aug. 21, 2018 STOCKHOLM , Aug. 21, 2018 /PRNewswire/ -- Important events January- June 2018 NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma's new subsidiary Fortify Therapeutics. The agreement has a total potential value of approximately $60 million USD including any royalties. NeuroVive conducts a preferential rights issue. NeuroVive...

NeuroVive Pharmaceutical AB Interim Report January - June 2018 PR Newswire STOCKHOLM, Aug. 21, 2018 NeuroVive out-licenses targeted LHON therapy to BridgeBio STOCKHOLM , Aug. 21, 2018 /PRNewswire/ -- Important events January- June 2018 NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma's new subsidiary Fortify Therapeutics. The agreement has a total potential value of approximately $60 million USD including any royalties. NeuroVive conducts a preferential rights issue. NeuroVive...

NeuroVive Pharmaceutical AB Interim Report January - June 2018 NeuroVive out-licenses targeted LHON therapy to BridgeBio PR Newswire STOCKHOLM, Aug. 21, 2018 STOCKHOLM , Aug. 21, 2018 /PRNewswire/ -- Important events January- June 2018 NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma's new subsidiary Fortify Therapeutics. The agreement has a total potential value of approximately $60 million USD including any royalties. NeuroVive conducts a preferential rights issue. NeuroVive...

NeuroVive Out-licenses Targeted LHON Therapy to BridgeBio Pharma's New Subsidiary Fortify Therapeutics PR Newswire LUND, Sweden and PALO ALTO, Calif., June 18, 2018 LUND, Sweden and PALO ALTO, Calif., June 18, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and BridgeBio Pharma today jointly announced that BridgeBio has entered into an exclusive licensing agreement for a subset of succinate prodrug chemistry under NeuroVive's NVP015 program. BridgeBio also...

Amended Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ) PR Newswire LUND, Sweden, May 31, 2018 LUND, Sweden , May 31, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF), the mitochondrial medicine company, today announced an increase of the number of shares and votes in NeuroVive of 39,244,644 as a result of a preferential rights issue in NeuroVive Pharmaceutical AB, approved at the Extraordinary General Meeting on 22 March 2018 . Today, the...

Amended Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ) PR Newswire LUND, Sweden, 31 May 2018 LUND, Sweden , 31 May 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF), the mitochondrial medicine company, today announced an increase of the number of shares and votes in NeuroVive of 39,244,644 as a result of a preferential rights issue in NeuroVive Pharmaceutical AB, approved at the Extraordinary General Meeting on 22 March 2018 . Today, the...

Amended Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ) PR Newswire LUND, Sweden, 31 May 2018 LUND, Sweden , 31 May 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF), the mitochondrial medicine company, today announced an increase of the number of shares and votes in NeuroVive of 39,244,644 as a result of a preferential rights issue in NeuroVive Pharmaceutical AB, approved at the Extraordinary General Meeting on 22 March 2018 . Today, the...

NeuroVive Pharmaceutical AB Interim Report January - March 2018 PR Newswire STOCKHOLM, May 22, 2018 STOCKHOLM , May 22, 2018 /PRNewswire/ -- Successful rights issue Business operations Important events January – March 2018 NeuroVive decided to conduct a rights issue for the continued development of the company's drug projects following shareholder approval at an Extraordinary General Meeting. The company reported positive efficacy data in an experimental model, entailing a breakthrough for the...

NeuroVive Pharmaceutical AB Interim Report January - March 2018 PR Newswire STOCKHOLM, May 22, 2018 STOCKHOLM , May 22, 2018 /PRNewswire/ -- Successful rights issue Business operations Important events January – March 2018 NeuroVive decided to conduct a rights issue for the continued development of the company's drug projects following shareholder approval at an Extraordinary General Meeting. The company reported positive efficacy data in an experimental model, entailing a breakthrough for the...